Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction

Rosemeire M. Kanashiro-Takeuchi, Bettina Heidecker, Guillaume Lamirault, Jennifer W. Dharamsi, Joshua M. Hare

Research output: Contribution to journalArticle

Abstract

Aldosterone receptor antagonism reduces mortality and improves post-myocardial infarction (Ml) remodeling. Because aldosterone and estrogen signaling pathways interact, we hypothesized that aldosterone blockade is sex-specific. Therefore, we investigated the mpact of eplerenone on left ventricular (LV) remodeling and gene expression of male infarcted rats versus female infarcted rats. Ml and Sham animals were randomized to receive eplerenone (100 mg/kg/day) or placebo 3 days post-surgery for 4 weeks and assessed by echocardiography. In the Ml placebo group, left ventricular end-diastolic dimension (LVEDD) increased from 7.3 ± 0.4 mm to 10.2 ± 1.0 mm (p <0.05) and ejection fraction (EF) decreased from 82.3 + 4% to 45.5 + 11% (p <0.05) in both sexes (p = NS between groups). Eplerenone attenuated LVEDD enlargement more effectively in females (8.8 ± 0.2 mm, p <0.05 vs. placebo) than in males (9.7 ± 0.2 mm, p = NS vs. placebo) and improved EF in females (56.7 ± 3%, p <0.05 vs. placebo) but not in males (50.6 + 3%, p = NS vs. placebo). Transcriptomic analysis using Rat_230-2.0 microarrays (Affymetrix) revealed that in females 19% of downregu-lated genes and 44% of upregulated genes post-MI were restored to normal by eplerenone. In contrast, eplerenone only restored 4% of overexpressed genes in males. Together, these data suggest that aldosterone blockade reduces Ml-induced cardiac remodeling and phenotypic alterations of gene expression preferentially in females than in males. The use of transcriptomic signatures to detect greater benefit of eplerenone in females has potential implications for personalized medicine.

Original languageEnglish (US)
Pages (from-to)134-142
Number of pages9
JournalClinical and Translational Science
Volume2
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Mineralocorticoid Receptors
Ventricular Remodeling
Gene expression
Myocardial Infarction
Placebos
Gene Expression
Aldosterone
Rats
montirelin
Genes
Echocardiography
Precision Medicine
Bioelectric potentials
Microarrays
Ambulatory Surgical Procedures
Surgery
Medicine
eplerenone
Estrogens
Animals

Keywords

  • Aldosterone antagonism
  • Feart failure
  • Gene expression
  • Myocardial infarction
  • Sex

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. / Kanashiro-Takeuchi, Rosemeire M.; Heidecker, Bettina; Lamirault, Guillaume; Dharamsi, Jennifer W.; Hare, Joshua M.

In: Clinical and Translational Science, Vol. 2, No. 2, 2009, p. 134-142.

Research output: Contribution to journalArticle

Kanashiro-Takeuchi, Rosemeire M. ; Heidecker, Bettina ; Lamirault, Guillaume ; Dharamsi, Jennifer W. ; Hare, Joshua M. / Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. In: Clinical and Translational Science. 2009 ; Vol. 2, No. 2. pp. 134-142.
@article{8c24357a95a34f9180b5be67253b4bac,
title = "Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction",
abstract = "Aldosterone receptor antagonism reduces mortality and improves post-myocardial infarction (Ml) remodeling. Because aldosterone and estrogen signaling pathways interact, we hypothesized that aldosterone blockade is sex-specific. Therefore, we investigated the mpact of eplerenone on left ventricular (LV) remodeling and gene expression of male infarcted rats versus female infarcted rats. Ml and Sham animals were randomized to receive eplerenone (100 mg/kg/day) or placebo 3 days post-surgery for 4 weeks and assessed by echocardiography. In the Ml placebo group, left ventricular end-diastolic dimension (LVEDD) increased from 7.3 ± 0.4 mm to 10.2 ± 1.0 mm (p <0.05) and ejection fraction (EF) decreased from 82.3 + 4{\%} to 45.5 + 11{\%} (p <0.05) in both sexes (p = NS between groups). Eplerenone attenuated LVEDD enlargement more effectively in females (8.8 ± 0.2 mm, p <0.05 vs. placebo) than in males (9.7 ± 0.2 mm, p = NS vs. placebo) and improved EF in females (56.7 ± 3{\%}, p <0.05 vs. placebo) but not in males (50.6 + 3{\%}, p = NS vs. placebo). Transcriptomic analysis using Rat_230-2.0 microarrays (Affymetrix) revealed that in females 19{\%} of downregu-lated genes and 44{\%} of upregulated genes post-MI were restored to normal by eplerenone. In contrast, eplerenone only restored 4{\%} of overexpressed genes in males. Together, these data suggest that aldosterone blockade reduces Ml-induced cardiac remodeling and phenotypic alterations of gene expression preferentially in females than in males. The use of transcriptomic signatures to detect greater benefit of eplerenone in females has potential implications for personalized medicine.",
keywords = "Aldosterone antagonism, Feart failure, Gene expression, Myocardial infarction, Sex",
author = "Kanashiro-Takeuchi, {Rosemeire M.} and Bettina Heidecker and Guillaume Lamirault and Dharamsi, {Jennifer W.} and Hare, {Joshua M.}",
year = "2009",
doi = "10.1111/j.1752-8062.2009.00094.x",
language = "English (US)",
volume = "2",
pages = "134--142",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction

AU - Kanashiro-Takeuchi, Rosemeire M.

AU - Heidecker, Bettina

AU - Lamirault, Guillaume

AU - Dharamsi, Jennifer W.

AU - Hare, Joshua M.

PY - 2009

Y1 - 2009

N2 - Aldosterone receptor antagonism reduces mortality and improves post-myocardial infarction (Ml) remodeling. Because aldosterone and estrogen signaling pathways interact, we hypothesized that aldosterone blockade is sex-specific. Therefore, we investigated the mpact of eplerenone on left ventricular (LV) remodeling and gene expression of male infarcted rats versus female infarcted rats. Ml and Sham animals were randomized to receive eplerenone (100 mg/kg/day) or placebo 3 days post-surgery for 4 weeks and assessed by echocardiography. In the Ml placebo group, left ventricular end-diastolic dimension (LVEDD) increased from 7.3 ± 0.4 mm to 10.2 ± 1.0 mm (p <0.05) and ejection fraction (EF) decreased from 82.3 + 4% to 45.5 + 11% (p <0.05) in both sexes (p = NS between groups). Eplerenone attenuated LVEDD enlargement more effectively in females (8.8 ± 0.2 mm, p <0.05 vs. placebo) than in males (9.7 ± 0.2 mm, p = NS vs. placebo) and improved EF in females (56.7 ± 3%, p <0.05 vs. placebo) but not in males (50.6 + 3%, p = NS vs. placebo). Transcriptomic analysis using Rat_230-2.0 microarrays (Affymetrix) revealed that in females 19% of downregu-lated genes and 44% of upregulated genes post-MI were restored to normal by eplerenone. In contrast, eplerenone only restored 4% of overexpressed genes in males. Together, these data suggest that aldosterone blockade reduces Ml-induced cardiac remodeling and phenotypic alterations of gene expression preferentially in females than in males. The use of transcriptomic signatures to detect greater benefit of eplerenone in females has potential implications for personalized medicine.

AB - Aldosterone receptor antagonism reduces mortality and improves post-myocardial infarction (Ml) remodeling. Because aldosterone and estrogen signaling pathways interact, we hypothesized that aldosterone blockade is sex-specific. Therefore, we investigated the mpact of eplerenone on left ventricular (LV) remodeling and gene expression of male infarcted rats versus female infarcted rats. Ml and Sham animals were randomized to receive eplerenone (100 mg/kg/day) or placebo 3 days post-surgery for 4 weeks and assessed by echocardiography. In the Ml placebo group, left ventricular end-diastolic dimension (LVEDD) increased from 7.3 ± 0.4 mm to 10.2 ± 1.0 mm (p <0.05) and ejection fraction (EF) decreased from 82.3 + 4% to 45.5 + 11% (p <0.05) in both sexes (p = NS between groups). Eplerenone attenuated LVEDD enlargement more effectively in females (8.8 ± 0.2 mm, p <0.05 vs. placebo) than in males (9.7 ± 0.2 mm, p = NS vs. placebo) and improved EF in females (56.7 ± 3%, p <0.05 vs. placebo) but not in males (50.6 + 3%, p = NS vs. placebo). Transcriptomic analysis using Rat_230-2.0 microarrays (Affymetrix) revealed that in females 19% of downregu-lated genes and 44% of upregulated genes post-MI were restored to normal by eplerenone. In contrast, eplerenone only restored 4% of overexpressed genes in males. Together, these data suggest that aldosterone blockade reduces Ml-induced cardiac remodeling and phenotypic alterations of gene expression preferentially in females than in males. The use of transcriptomic signatures to detect greater benefit of eplerenone in females has potential implications for personalized medicine.

KW - Aldosterone antagonism

KW - Feart failure

KW - Gene expression

KW - Myocardial infarction

KW - Sex

UR - http://www.scopus.com/inward/record.url?scp=77952417047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952417047&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2009.00094.x

DO - 10.1111/j.1752-8062.2009.00094.x

M3 - Article

VL - 2

SP - 134

EP - 142

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 2

ER -